



Annual Report 2023

The board of Trustees of GAFFI at the end of 2023 reflected the international work of GAFFI and was composed of Oddi Aasheim, Yasuaki Mori, Professor Juan Luis Rodriguez Tudela, Professor David Perlin, David Allmond, Skhumbuzo Ngozwana and Dr. Nkechi Azie. The executive board consisted of Oddi Aasheim (Chair and Chief Strategy Officer), Juan Luis Rodríguez Tudela (Interim CEO, Director for Latin America Programmes), Emma Orefuwa (Director for African Programmes) and Timothy Moss (Head of Finance and Governance). GAFFI and GAFFI UK have identical Board membership to facilitate achieving GAFFI's goals.

Aims

- **GAFFI's strategy** focuses on enhancing outcomes by prioritising timely diagnosis and ensuring access to treatment for fungal infections in immunocompromised patients residing in low- to middle-income countries (LMICs);
- **GAFFI presents a well-established model** which empowers healthcare professionals responsible for managing HIV in LMICs, enhancing outcomes in opportunistic fungal infections among people who live with HIV;
- **GAFFI actively cultivates and empowers regional and local hubs and networks**, enabling them to enhance access to cost-effective and efficient diagnostics including detection of antifungal resistance and treatments.

Donors and supporters

We would again like to thank all those who continue to support GAFFI with generous donations, donations in kind (including office space), and our country



Global Action For Fungal Infections

www.gaffi.org

Ambassadors. Fuller details of our supports and Ambassadors are available on our website.

New Focused Strategy and Plans

GAFFI is undergoing a full-scale transformation to elevate its impact. The Board has been strengthened through the recruitment of high-profile leaders representing the regions and focus areas of GAFFI. GAFFI has also implemented a strategic focus on reducing mortality through access to diagnosis and treatment for Fungal Disease by providing the needed tools and expertise hubs to diagnose the Fungal Diseases that affect the patient, including detection of antifungal resistance. This includes implementation of Diagnostic Laboratory Hubs as soon as practically possible, building on our successful Latin America model.

GAFFI's achievements in 2023 include:

1. The signature of a Memorandum of Understanding with the Pan-American Health Organisation (PAHO) with the purpose to formalise the cooperation between the parties for decreasing the impact of Fungal Disease in Latin America and the Caribbean, implementing public health interventions, surveillance, and research strategies targeted at the most important fungal pathogens.
2. Expanding further activities with the WHO regarding the release of the Fungal Pathogens Priority List.
3. An intervention project in collaboration with the Mycology Branch of the US Centre for Diseases Control (CDC) entitled: "Scaling up Access to Diagnosis for Fungal Disease Following Successful Proof of Concept in Guatemala".
4. An intervention project in collaboration with JYLAG entitled: "A Diagnostic Laboratory Hub for global access to diagnoses of Fungal Disease in Santa Fe province, Argentina".

Global Action For Fungal Infections

www.gaffi.org



5. Member of the advisory committee of the Medical Research Council (MRC) Centre for Medical Mycology at the University of Exeter for establishing a Centre for Medical Mycology LATAM Unit at Brazil.
6. Partner with Africa CDC in establishing hubs and formal expertise and ambassador networks in fungal disease across Africa.
7. Building on the learning and insights gained from the Latin America programmes, for similar activities in Africa.
8. Develop partnerships for GAFFI that will 'add fungal disease' as an additional aspect to planned projects, notably in the context of AMR programmes, but also others.
9. Further professionalisation of GAFFI with new Board members and strengthening the leadership team.

Oddi Aasheim
President/président
20/05/2024